Metformin can inhibit the mTOR pathway by activating AMPK, which may lead to reprogramming of cancer metabolism, which in turn exerts inhibitory effects on cancers such as liver, colorectal and breast cancers [38, 58, 59]. Here, MTOR is linked to breast carcinoma.